Top Markets
Coin of the day
NeuroSense Therapeutics Ltd. NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSN
Rank in Stocks #31074
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical... NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Share Price
$0.404
Market Cap
$14.28M
Change (1 day)
-10.42%
Change (1 year)
-67.68%
Country
IL
Trade NeuroSense Therapeutics Ltd. (NRSN)

Category

Earnings for NeuroSense Therapeutics Ltd. (NRSN)
Earnings in 2026 TTM: 0
According to NeuroSense Therapeutics Ltd. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for NeuroSense Therapeutics Ltd. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$3.01B -
BE